Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
249.8 CHF | -1.42% | 0.00% | +2.17% |
06-25 | Halozyme Therapeutics Says Roche's OCREVUS SC With ENHANZE Gets European Commission Approval | MT |
06-25 | Roche: approval of Ocrevus SC in Europe | CF |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.17% | 229B | |
+54.89% | 815B | |
+44.25% | 654B | |
-6.64% | 354B | |
+21.98% | 337B | |
+10.22% | 302B | |
+18.10% | 247B | |
+12.94% | 219B | |
+9.67% | 171B | |
-3.47% | 159B |
- Stock Market
- Equities
- ROG Stock
- News Roche Holding AG
- Transcript : Roche Holding AG - Special Call